Thyrocare Tech.

Why is Thyrocare Technologies Ltd falling/rising?

As of 08-Jul, Thyrocare Technologies Ltd's stock price is at 522.25, reflecting a decline of 1.8% and a total drop of 6.11% over the last four days. Despite a high dividend yield and increased investor participation, the stock faces downward pressure due to recent price trends and pledged promoter shares.

As of 08-Jul, Thyrocare Technologies Ltd's stock price is falling, currently at 522.25, which reflects a decrease of 9.55 or 1.8%. The stock has been experiencing a consecutive decline over the last four days, resulting in a total drop of 6.11% during this period. Today, it opened with a loss of 2.22% and reached an intraday low of Rs 512.5, marking a decline of 3.63%.<BR><BR>Despite some positive indicators such as a high dividend yield of 3.08% and rising investor participation with a delivery volume increase of 20.69% against the 5-day average, the stock's performance has been negatively impacted by its recent trend of falling prices. Additionally, the stock is trading at a premium compared to its peers, which may contribute to investor caution. The presence of 100% of promoter shares being pledged also adds to the downward pressure on the stock, particularly in a falling market. <BR><BR>Overall, while Thyrocare Technologies Ltd has shown strong long-term performance and management efficiency, the current market conditions and recent price movements indicate a downward trend in its stock price.

Which are the latest news on Thyrocare Tech.?

What does Thyrocare Tech. do?

Thyrocare Technologies Ltd is a healthcare services company specializing in affordable diagnostic services. As of March 2026, it reported net sales of 224 Cr and a net profit of 47 Cr, with a market cap of INR 8,716 Cr.

Overview:<BR>Thyrocare Technologies Ltd operates in the healthcare services industry, providing quality diagnostic services at affordable costs.<BR><BR>History:<BR>Incorporated in January 2000, Thyrocare Technologies Ltd has been active in the healthcare sector and reported net sales and net profit for the quarter ending March 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 224 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 47 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 8,716 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 50.00 <BR>Industry P/E: 60 <BR>Dividend Yield: 1.70% <BR>Debt-Equity: -0.29 <BR>Return on Equity: 28.68% <BR>Price to Book: 14.90<BR><BR>Contact Details:<BR>Address: D-37/1 TTC Industrial Area, MIDC Turbhe Navi Mumbai Maharashtra : 400703 <BR>Tel: 91-22-27622762 <BR>Email: investor_relations@thyrocare.com <BR>Website: http://www.thyrocare.com

How big is Thyrocare Tech.?

As of 10th June, Thyrocare Technologies Ltd has a market capitalization of 8,716.00 Cr, with recent net sales of 829.04 Cr and net profit of 163.05 Cr over the last four quarters.

As of 10th June, <BR><BR>Market Cap: Thyrocare Technologies Ltd has a market capitalization of 8,716.00 Cr, classifying it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 829.04 Cr, while the sum of Net Profit for the same period is 163.05 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2026, with Shareholder's Funds amounting to 585.50 Cr and Total Assets valued at 731.56 Cr.

Who are in the management team of Thyrocare Tech.?

The management team of Thyrocare Technologies includes Rahul Guha (Managing Director & CEO), Ramjee Dorai (Company Secretary), and several independent and non-executive directors, bringing diverse expertise to the company's governance.

The management team of Thyrocare Technologies includes the following individuals:<BR><BR>1. **Rahul Guha** - Managing Director & CEO<BR>2. **Ramjee Dorai** - Company Secretary & Compliance Officer<BR>3. **Gopal Shivram Hegde** - Independent Director<BR>4. **Neetin Shivajirao Desai** - Independent Director<BR>5. **Vishwas Madhav Kulkarni** - Independent Director<BR>6. **Indumati Gopinathan** - Independent Director<BR>7. **Dhaval Shah** - Non-Executive & Non-Independent Director<BR>8. **Dharmil Sheth** - Non-Executive & Non-Independent Director<BR>9. **Hardik Dedhia** - Non-Executive & Non-Independent Director<BR>10. **Prapti Ishwar Gilada** - Independent Director<BR>11. **Harshil Jiten Vora** - Independent Director<BR><BR>This diverse team brings a range of expertise to the company, contributing to its strategic direction and governance.

Who are the peers of the Thyrocare Tech.?

Thyrocare Tech.'s peers include Syngene Intl., Poly Medicure, Vijaya Diagnost., Indegene, Metropolis Health, Suven Life Sciences, Vimta Labs, Krsnaa Diagnost., and Suraksha Diagno. Most peers show Below Average growth and management risk, with Thyrocare Tech. achieving a 1-year return of 62.27%, significantly higher than its peers.

Peers: The peers of Thyrocare Tech. are Syngene Intl., Poly Medicure, Vijaya Diagnost., Indegene, Metropolis Healt, Suven Life Scie., Vimta Labs, Krsnaa Diagnost., and Suraksha Diagno.<BR><BR>Quality Snapshot: Excellent management risk is observed at Syngene Intl., Poly Medicure, Vijaya Diagnost., Metropolis Healt., and Suraksha Diagno., while Average management risk is found at Indegene, Vimta Labs, and Krsnaa Diagnost., and the rest have Below Average management risk. All peers exhibit Below Average growth except for Suraksha Diagno., which has Good growth, while the rest, including Thyrocare Tech., show Below Average growth. Excellent capital structure is noted for Syngene Intl., Poly Medicure, Vijaya Diagnost., Indegene, Metropolis Healt., Vimta Labs, and Krsnaa Diagnost., while Suven Life Scie. has Below Average capital structure.<BR><BR>Return Snapshot: Vijaya Diagnost. has the highest 1-year return at 36.39%, while Poly Medicure has the lowest at -36.89%. Thyrocare Tech.'s 1-year return of 62.27% is significantly higher than both. Additionally, peers such as Suven Life Scie., Krsnaa Diagnost., and Suraksha Diagno. have negative six-month returns.

Are Thyrocare Technologies Ltd latest results good or bad?

Thyrocare Technologies Ltd's latest results are strong, with a net profit of ₹47.12 crore and a 19.66% revenue increase in Q4 FY26, alongside improved operating margins. However, the stock's high valuations raise concerns about sustainability, suggesting investors should exercise caution.

Thyrocare Technologies Ltd's latest results can be considered quite strong overall. In the fourth quarter of FY26, the company reported a significant net profit of ₹47.12 crore, which represents a remarkable year-on-year growth of 117.14%. Additionally, revenue for the same period reached ₹223.95 crore, showing a healthy increase of 19.66% compared to the previous year.<BR><BR>The operating margin also improved, reaching an all-time high of 33.53%, up from 30.83% in the same quarter last year. This indicates effective cost management and improved pricing power. Furthermore, the company demonstrated strong operational efficiency, with a return on equity of 23.91%, which is notably higher than the industry average.<BR><BR>Despite these positive results, the stock trades at elevated valuations, with a price-to-earnings ratio of approximately 53 times and a price-to-book value of 14.08 times. This raises some concerns about the sustainability of such high valuations and the potential for future upside. <BR><BR>Overall, while the operational performance is impressive and has led to a strong stock rally, investors should be cautious due to the high valuation multiples, which suggest limited margin of safety.

Should I buy, sell or hold Thyrocare Technologies Ltd?

When is the next results date for Thyrocare Technologies Ltd?

The next results date for Thyrocare Technologies Ltd is 07 May 2026.

The next results date for Thyrocare Technologies Ltd is scheduled for 07 May 2026.

Is Thyrocare Tech. technically bullish or bearish?

As of December 2, 2025, Thyrocare Tech. shows a mildly bullish trend supported by bullish MACD and moving averages, but tempered by a mildly bearish KST and Dow Theory signals, indicating caution in the current market.

As of 2 December 2025, the technical trend for Thyrocare Tech. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by a bullish MACD on both weekly and monthly time frames, and daily moving averages indicating bullish momentum. However, the KST shows a mildly bearish signal on the weekly chart, which tempers the overall bullish outlook. Bollinger Bands are also indicating mildly bullish conditions on both weekly and monthly charts. The RSI shows no significant signals, and Dow Theory reflects a mildly bearish stance on the weekly chart with no trend on the monthly. Overall, while there are bullish indicators present, the mildly bearish signals suggest caution in the current market environment.

What is the bonus history of Thyrocare Tech.?

Thyrocare Technologies Ltd recently announced a 2:1 bonus issue, with an ex-date of November 28, 2025. Shareholders will receive two additional shares for every one share held as of that date.

Thyrocare Technologies Ltd has a recent bonus issue where they announced a 2:1 bonus. The ex-date for this bonus is set for November 28, 2025. This means that shareholders will receive two additional shares for every one share they hold as of the record date, which is also November 28, 2025. If you have any further questions about Thyrocare or its corporate actions, feel free to ask!

How has been the historical performance of Thyrocare Tech.?

Thyrocare Tech. has shown steady growth in net sales and profits, with net sales increasing from 402.91 Cr in Mar'19 to 687.35 Cr in Mar'25, and profit after tax rising to 92.19 Cr in Mar'25. The company has demonstrated resilience with improved earnings per share and strong cash flow from operating activities.

Answer:<BR>The historical performance of Thyrocare Tech. shows a steady growth in net sales and profits over the years, with a notable increase in recent years.<BR><BR>Breakdown:<BR>Thyrocare Tech. has demonstrated a consistent upward trend in net sales, rising from 402.91 Cr in Mar'19 to 687.35 Cr in Mar'25. Total operating income followed a similar trajectory, reaching 687.35 Cr in Mar'25, up from 571.88 Cr in Mar'24. The company's total expenditure also increased, amounting to 496.99 Cr in Mar'25 compared to 434.45 Cr in Mar'24. Operating profit, however, saw fluctuations, peaking at 264.14 Cr in Mar'22 before declining to 205.19 Cr in Mar'25. Profit before tax increased to 146.88 Cr in Mar'25 from 95.59 Cr in Mar'24, while profit after tax rose to 92.19 Cr in Mar'25, up from 69.10 Cr in Mar'24. The earnings per share (EPS) improved to 17.27 in Mar'25 from 13.36 in Mar'24. On the balance sheet, total assets grew to 684.22 Cr in Mar'25 from 629.06 Cr in Mar'24, while total liabilities also increased to 684.22 Cr in Mar'25. Cash flow from operating activities showed a positive trend, reaching 191 Cr in Mar'25, indicating strong operational performance. Overall, Thyrocare Tech. has shown resilience and growth in its financial metrics over the years.

Has Thyrocare Tech. declared dividend?

Yes, Thyrocare Technologies Ltd has declared a 70% dividend, amounting to ₹21 per share, with an ex-date of July 25, 2025. The company has demonstrated strong total returns across various periods, reflecting its commitment to shareholder value.

Thyrocare Technologies Ltd has declared a 70% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 70%<BR>- Amount per share: 21<BR>- Ex-date: Jul-25-2025<BR><BR>Dividend Yield: 1.69%.<BR><BR>Total Returns by Period:<BR>In the last 3 months, the price return was 6.28%, the dividend return was 2.37%, resulting in a total return of 8.65%.<BR><BR>Over the past 6 months, the price return reached 79.35%, with a dividend return of 3.81%, culminating in a total return of 83.16%.<BR><BR>For the 1-year period, the price return was 43.61%, the dividend return was 3.11%, leading to a total return of 46.72%.<BR><BR>In the 2-year span, the price return stood at 123.52%, with a dividend return of 8.53%, resulting in a total return of 132.05%.<BR><BR>Over the last 3 years, the price return was 89.03%, the dividend return was 9.93%, giving a total return of 98.96%.<BR><BR>In the 4-year period, the price return was 11.77%, with a dividend return of 6.78%, resulting in a total return of 18.55%.<BR><BR>Finally, in the 5-year period, the price return was 25.73%, the dividend return was 9.86%, leading to a total return of 35.59%.<BR><BR>Overall, Thyrocare Technologies Ltd has shown a strong performance with significant total returns across various periods, supported by a declared dividend, indicating a commitment to returning value to shareholders.

Who are the top shareholders of the Thyrocare Tech.?

The top shareholder of Thyrocare Technologies is Docon Technologies Private Limited, holding 71.06%. Other significant shareholders include Nippon Life India Trustee Ltd at 7.05%, mutual funds with 12.97%, foreign institutional investors at 2.41%, and individual investors with 9.21%.

The top shareholders of Thyrocare Technologies include a mix of promoters, mutual funds, and individual investors. The majority shareholder is Docon Technologies Private Limited, which holds a significant 71.06% of the company. Promoters collectively have pledged their holdings entirely. Among public shareholders, Nippon Life India Trustee Ltd, representing the Nippon India Small Cap Fund, is the largest with a holding of 7.05%. Additionally, mutual funds account for 12.97% of the shares, held by seven different schemes, while foreign institutional investors (FIIs) hold 2.41%. Individual investors collectively own 9.21% of the company.

Is Thyrocare Tech. overvalued or undervalued?

As of July 3, 2025, Thyrocare Technologies is considered very expensive and overvalued due to its high PE ratio of 59.09, Price to Book Value of 9.91, and EV to EBITDA of 27.57, despite a strong ROCE of 35.59% and a one-year stock return of 59.53%.

As of 3 July 2025, the valuation grade for Thyrocare Technologies has moved from expensive to very expensive, indicating a significant concern regarding its current pricing. The company is deemed overvalued based on its high PE ratio of 59.09, a Price to Book Value of 9.91, and an EV to EBITDA of 27.57. These ratios suggest that investors are paying a premium for the stock relative to its earnings and book value.<BR><BR>In comparison to its peers, Thyrocare's valuation appears excessive, especially when looking at Max Healthcare, which has a PE of 112.13, and Apollo Hospitals with a PE of 75.12. While Thyrocare's ROCE stands at a robust 35.59%, the high PEG ratio of 2.01 further emphasizes the overvaluation concern. Additionally, despite a strong one-year stock return of 59.53% compared to the Sensex's 4.07%, the elevated valuation metrics suggest that the stock may not sustain this growth, reinforcing the conclusion that Thyrocare Technologies is overvalued.